Today’s Research Reports on Stocks to Watch: Fitbit and GoPro

Fitbit shares may have seen red yesterday but there’s no denying it was an exciting week for the company. The FDA this week announced a new program offering "fast track" for nine technology companies to gain approval and Fitbit was one of them. Shares of GoPro closed down yesterday despite the company announcing two new cameras ahead of the holiday season.

RDI Initiates Coverage on:

Fitbit, Inc.

GoPro, Inc.

Fitbit, Inc. shares closed down 1% on Thursday with nearly 6.5 million shares traded. There have been several exciting developments for the wearable watch maker. The stock saw big gains earlier in the week when it was announced that the FDA has selected nine tech companies for a pilot program and Fitbit was one of them. The program may allow the companies to avoid regulations on health products. Fitbit was chosen for its partnership with DexCom for glucose monitoring on the Ionic smartwatch. The company also announced on Monday that its Fitbit Ionic smartwatch and Fitbit Flyer wireless headphones will go on sale starting Sunday.

Access RDI’s Fitbit, Inc. Research Report at:

GoPro, Inc. shares closed down 1.80% on Thursday with nearly 8 million shares traded. Despite the decline, it was an exciting day for the action-camera maker, as it announced two new cameras at a media event in San Francisco. The company announced the Hero 6 Black, a newer version of its flagship model, as well as the Fusion camera, GoPro’s first 360-degree camera for taking videos that can be played back on virtual-reality headsets. At a price of $499.99, the Hero 6 is now on sale and takes video in 4k ultra-high-definition resolution at 60 frames per second. The company’s Fusion camera shoots 5.2k videos at 30 frames per second and 3k videos at 60 frames per second. It has a price of $699.99 and will start shipping in November.

Access RDI’s GoPro, Inc. Research Report at:

Our Actionable Research on Fitbit, Inc. (NYSE: FIT) and GoPro, Inc. (NASDQ: GPRO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and reviewed by Nadia Noorani, CFA® charter holder. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.